Fundsmith LLP · 2025 · Semi-annual letter
Terry Smith reports Fundsmith Equity's first-half 2025 performance against the MSCI World Index and comparators.
Terry Smith reports that the Fundsmith Equity Fund fell 1.9% in the first half of 2025, two percentage points less than the MSCI World Index in sterling. Philip Morris, Meta Platforms, Microsoft, IDEXX and L'Oréal added most, while Novo Nordisk and Coloplast, both Danish companies controlled by foundations, caused more than all of the underperformance. The pound's rise from $1.25 to $1.37 also cut sterling returns; the dollar fund rose 6.3%. The Fund began buying Zoetis, Intuit and EssilorLuxottica and sold PepsiCo and Brown-Forman, with turnover of 9.2%.
Another Danish medical company, Coloplast, was also amongst our largest detractors.Show in the letter ›
Coloplast was a company whose revenue growth rate was metronomic.Show in the letter ›
Both Novo and Coloplast are controlled by foundations which we have seen as a strength in terms of their ability to make good long-term decisions.Show in the letter ›
During the period we began accumulating stakes in Zoetis, the animal health company, Intuit, the accounting software business and EssilorLuxottica the global eyewear manufacturer and we sold our positions in PepsiCo and Brown-Forman.Show in the letter ›